Novel applications of TRPV4 agonist GSK1016790A

A GSK1016790A, agonist technology, applied in the field of medicine, can solve problems such as diabetes cognitive function decline, achieve the effect of increasing new object recognition ability, high clinical application value and development prospect, and increasing preference

Inactive Publication Date: 2020-05-26
NANHUA UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no report in the literature that GSK1016790A treats and alleviates cognitive declin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel applications of TRPV4 agonist GSK1016790A
  • Novel applications of TRPV4 agonist GSK1016790A
  • Novel applications of TRPV4 agonist GSK1016790A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Novel Object Recognition (NOR) Experimental Investigation of the Effect of TRPV4 Agonist GSK1016790A on Novel Object Recognition in STZ-Induced Cognitive Impairment Model Mice

[0026] Animals: 24 male ICR mice, 3 months old, weighing about 30-40 g. Animals were kept at room temperature (22±2)°C, humidity (45%-65%) and light and dark (12h:12h) environment, free to eat and drink.

[0027] Animal grouping and treatment: mice were divided into 3 groups according to the random number table method: vehicle control group (DMSO+NS, n=8), diabetic cognitive impairment model group (DMSO+STZ, n=8), GSK1016790A group (GSK +STZ, n=8), the mice were given intraperitoneal injection of streptozotocin (STZ, 55mg / kg) after daily fasting for 6h (8:30-14:30) for five consecutive days, to establish diabetic cognitive impairment Model. Mice in the DMSO+NS group were injected with an equal volume of normal saline in the same way. GSK1016790A (0.125mg / kg) or its vehicle DMSO was...

Embodiment 2

[0031] Example 2: Investigation of the effect of TRPV4 agonist GSK1016790A on novel location recognition in STZ-induced cognitive impairment model mice

[0032] Animals: 24 male ICR mice, 3 months old, weighing about 30-40 g. Animals were kept at room temperature (22±2)°C, humidity (45%-65%) and light and dark (12h:12h) environment, free to eat and drink.

[0033] Animal grouping and treatment: Mice were divided into 3 groups according to the random number table method: vehicle control group (DMSO+ NS, n=8), diabetic cognitive impairment model group (DMSO+STZ, n=8), GSK1016790A group (GSK+ STZ, n=8), the mice were fasted for 6 hours (8:30-14:30) and given intraperitoneal injection of streptozotocin (STZ, 55mg / kg) for five consecutive days to establish a diabetic cognitive impairment model . Mice in the DMSO+NS group were injected with an equal volume of normal saline in the same way. GSK1016790A (0.125mg / kg) or its vehicle DMSO was injected intraperitoneally continuously fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, discloses new applications of a TRPV4 agonist GSK1016790A, and particularly relates to an application of the TRPV4 agonist GSK1016790A in the preparation of a medicine for treating diabetes cognitive decline. Experiments show that the TRPV4 agonist GSK1016790A can obviously improve the recognition capability of STZ-induced learning and memory impairment mice on new objects, can obviously increase the preference of mice to new positions, can be used for preparing the medicine for treating diabetes cognitive decline, and has high clinical application value and development prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the new application of TRPV4 agonist GSK1016790A in the preparation of medicines for treating neurological diseases related to cognitive function decline, in particular to the application of TRPV4 agonist GSK1016790A in the preparation of medicines for treating cognitive function decline in diabetes . Background technique [0002] Diabetes is a global public health problem that seriously affects people's health, and its prevalence is on the rise worldwide. It is predicted that by 2040, there will be 642 million diabetic patients worldwide, of which China will account for 151 million (Lancet , 2016, 387(10027):1513-1530). Diabetes is accompanied by many complications, such as heart disease, eye disease, kidney disease, skin disease, neuropathy, etc. These complications seriously affect people's quality of life (Biomed Res Int, 2013, 2013: 924327). Both type I and type II diabe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61P25/28A61P3/10
CPCA61K31/496A61P3/10A61P25/28
Inventor 徐杨罗丹何洁秦宇麒曹文宇张圆时萌萌李威邓颖成
Owner NANHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap